Paulsen I T, Brown M H, Skurray R A
School of Biological Sciences, University of Sydney, New South Wales, Australia.
Microbiol Rev. 1996 Dec;60(4):575-608. doi: 10.1128/mr.60.4.575-608.1996.
Multidrug efflux systems display the ability to transport a variety of structurally unrelated drugs from a cell and consequently are capable of conferring resistance to a diverse range of chemotherapeutic agents. This review examines multidrug efflux systems which use the proton motive force to drive drug transport. These proteins are likely to operate as multidrug/proton antiporters and have been identified in both prokaryotes and eukaryotes. Such proton-dependent multidrug efflux proteins belong to three distinct families or superfamilies of transport proteins: the major facilitator superfamily (MFS), the small multidrug resistance (SMR) family, and the resistance/ nodulation/cell division (RND) family. The MFS consists of symporters, antiporters, and uniporters with either 12 or 14 transmembrane-spanning segments (TMS), and we show that within the MFS, three separate families include various multidrug/proton antiport proteins. The SMR family consists of proteins with four TMS, and the multidrug efflux proteins within this family are the smallest known secondary transporters. The RND family consists of 12-TMS transport proteins and includes a number of multidrug efflux proteins with particularly broad substrate specificity. In gram-negative bacteria, some multidrug efflux systems require two auxiliary constituents, which might enable drug transport to occur across both membranes of the cell envelope. These auxiliary constituents belong to the membrane fusion protein and the outer membrane factor families, respectively. This review examines in detail each of the characterized proton-linked multidrug efflux systems. The molecular basis of the broad substrate specificity of these transporters is discussed. The surprisingly wide distribution of multidrug efflux systems and their multiplicity in single organisms, with Escherichia coli, for instance, possessing at least nine proton-dependent multidrug efflux systems with overlapping specificities, is examined. We also discuss whether the normal physiological role of the multidrug efflux systems is to protect the cell from toxic compounds or whether they fulfil primary functions unrelated to drug resistance and only efflux multiple drugs fortuitously or opportunistically.
多药外排系统具有将多种结构不相关的药物从细胞中转运出去的能力,因此能够赋予细胞对多种化疗药物的抗性。本综述探讨了利用质子动力驱动药物转运的多药外排系统。这些蛋白质可能作为多药/质子反向转运体发挥作用,并且已在原核生物和真核生物中被鉴定出来。这种依赖质子的多药外排蛋白属于三个不同的转运蛋白家族或超家族:主要易化子超家族(MFS)、小多药抗性(SMR)家族和抗性/结瘤/细胞分裂(RND)家族。MFS由具有12个或14个跨膜区段(TMS)的同向转运体、反向转运体和单向转运体组成,我们发现,在MFS内,三个不同的家族包含各种多药/质子反向转运蛋白。SMR家族由具有4个TMS的蛋白质组成,该家族内的多药外排蛋白是已知最小的次级转运体。RND家族由具有12个TMS的转运蛋白组成,包括一些底物特异性特别广泛的多药外排蛋白。在革兰氏阴性菌中,一些多药外排系统需要两个辅助成分,这可能使药物能够跨细胞膜的两层膜进行转运。这些辅助成分分别属于膜融合蛋白家族和外膜因子家族。本综述详细探讨了每个已表征的质子偶联多药外排系统。讨论了这些转运体广泛底物特异性的分子基础。研究了多药外排系统令人惊讶的广泛分布及其在单个生物体中的多样性,例如大肠杆菌至少拥有9个具有重叠特异性的依赖质子的多药外排系统。我们还讨论了多药外排系统的正常生理作用是保护细胞免受有毒化合物的侵害,还是它们履行与耐药性无关的主要功能,只是偶然或机会性地外排多种药物。